85 related articles for article (PubMed ID: 27049678)
1. VP1 crystal structure-guided exploration and optimization of 4,5-dimethoxybenzene-based inhibitors of rhinovirus 14 infection.
Da Costa L; Roche M; Scheers E; Coluccia A; Neyts J; Terme T; Leyssen P; Silvestri R; Vanelle P
Eur J Med Chem; 2016 Jun; 115():453-62. PubMed ID: 27049678
[TBL] [Abstract][Full Text] [Related]
2. A novel benzonitrile analogue inhibits rhinovirus replication.
Lacroix C; Querol-Audí J; Roche M; Franco D; Froeyen M; Guerra P; Terme T; Vanelle P; Verdaguer N; Neyts J; Leyssen P
J Antimicrob Chemother; 2014 Oct; 69(10):2723-32. PubMed ID: 24948704
[TBL] [Abstract][Full Text] [Related]
3. Heterocyclic pharmacochemistry of new rhinovirus antiviral agents: A combined computational and experimental study.
Da Costa L; Scheers E; Coluccia A; Rosetti A; Roche M; Neyts J; Terme T; Cirilli R; Mirabelli C; Silvestri R; Vanelle P
Eur J Med Chem; 2017 Nov; 140():528-541. PubMed ID: 28987610
[TBL] [Abstract][Full Text] [Related]
4. Human rhinovirus 3 at 3.0 A resolution.
Zhao R; Pevear DC; Kremer MJ; Giranda VL; Kofron JA; Kuhn RJ; Rossmann MG
Structure; 1996 Oct; 4(10):1205-20. PubMed ID: 8939746
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and activity of piperazine-containing antirhinoviral agents and crystal structure of SDZ 880-061 bound to human rhinovirus 14.
Oren DA; Zhang A; Nesvadba H; Rosenwirth B; Arnold E
J Mol Biol; 1996 May; 259(1):120-34. PubMed ID: 8648640
[TBL] [Abstract][Full Text] [Related]
6. A Novel Series of Highly Potent Small Molecule Inhibitors of Rhinovirus Replication.
Kim J; Jung YK; Kim C; Shin JS; Scheers E; Lee JY; Han SB; Lee CK; Neyts J; Ha JD; Jung YS
J Med Chem; 2017 Jul; 60(13):5472-5492. PubMed ID: 28581749
[TBL] [Abstract][Full Text] [Related]
7. Synthesis, biological activity and structure-activity relationship of 4,5-dimethoxybenzene derivatives inhibitor of rhinovirus 14 infection.
Roche M; Lacroix C; Khoumeri O; Franco D; Neyts J; Terme T; Leyssen P; Vanelle P
Eur J Med Chem; 2014 Apr; 76():445-59. PubMed ID: 24602790
[TBL] [Abstract][Full Text] [Related]
8. VP1 sequencing of all human rhinovirus serotypes: insights into genus phylogeny and susceptibility to antiviral capsid-binding compounds.
Ledford RM; Patel NR; Demenczuk TM; Watanyar A; Herbertz T; Collett MS; Pevear DC
J Virol; 2004 Apr; 78(7):3663-74. PubMed ID: 15016887
[TBL] [Abstract][Full Text] [Related]
9. Human rhinovirus 14 complexed with fragments of active antiviral compounds.
Bibler-Muckelbauer JK; Kremer MJ; Rossmann MG; Diana GD; Dutko FJ; Pevear DC; McKinlay MA
Virology; 1994 Jul; 202(1):360-9. PubMed ID: 8009848
[TBL] [Abstract][Full Text] [Related]
10. In vitro characterisation of a pleconaril/pirodavir-like compound with potent activity against rhinoviruses.
Lacroix C; Laconi S; Angius F; Coluccia A; Silvestri R; Pompei R; Neyts J; Leyssen P
Virol J; 2015 Jul; 12():106. PubMed ID: 26169596
[TBL] [Abstract][Full Text] [Related]
11. Structure determination of antiviral compound SCH 38057 complexed with human rhinovirus 14.
Zhang A; Nanni RG; Li T; Arnold GF; Oren DA; Jacobo-Molina A; Williams RL; Kamer G; Rubenstein DA; Li Y
J Mol Biol; 1993 Apr; 230(3):857-67. PubMed ID: 8386772
[TBL] [Abstract][Full Text] [Related]
12. Phenylpropenoids from Bupleurum fruticosum as Anti-Human Rhinovirus Species A Selective Capsid Binders.
Fois B; Bianco G; Sonar VP; Distinto S; Maccioni E; Meleddu R; Melis C; Marras L; Pompei R; Floris C; Caboni P; Cottiglia F
J Nat Prod; 2017 Oct; 80(10):2799-2806. PubMed ID: 29039946
[TBL] [Abstract][Full Text] [Related]
13. Structure-Based Drug Design of Potent Pyrazole Derivatives against Rhinovirus Replication.
Da Costa L; Scheers E; Coluccia A; Casulli A; Roche M; Di Giorgio C; Neyts J; Terme T; Cirilli R; La Regina G; Silvestri R; Mirabelli C; Vanelle P
J Med Chem; 2018 Sep; 61(18):8402-8416. PubMed ID: 30153009
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and anti-rhinovirus activity of novel 3-[2-(pyridinyl)vinyl]substituted -2H-chromenes and -4H-chromen-4-ones.
Conti C; Proietti Monaco L; Desideri N
Bioorg Med Chem; 2014 Feb; 22(3):1201-7. PubMed ID: 24360829
[TBL] [Abstract][Full Text] [Related]
15. 3-Phenylalkyl-2H-chromenes and -chromans as novel rhinovirus infection inhibitors.
Conti C; Proietti Monaco L; Desideri N
Bioorg Med Chem; 2017 Apr; 25(7):2074-2083. PubMed ID: 28242170
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and in vitro evaluation of novel chroman-4-one, chroman, and 2H-chromene derivatives as human rhinovirus capsid-binding inhibitors.
Conti C; Proietti Monaco L; Desideri N
Bioorg Med Chem; 2011 Dec; 19(24):7357-64. PubMed ID: 22088306
[TBL] [Abstract][Full Text] [Related]
17. The structure of human rhinovirus 16.
Oliveira MA; Zhao R; Lee WM; Kremer MJ; Minor I; Rueckert RR; Diana GD; Pevear DC; Dutko FJ; McKinlay MA
Structure; 1993 Sep; 1(1):51-68. PubMed ID: 7915182
[TBL] [Abstract][Full Text] [Related]
18. Identification of epidermal growth factor receptor-tyrosine kinase inhibitor targeting the VP1 pocket of human rhinovirus.
Miah M; Davis AM; Hannoun C; Said JS; Fitzek M; Preston M; Smith D; Uwamariya C; Kärmander A; Lundbäck T; Bergström T; Trybala E
Antimicrob Agents Chemother; 2024 Mar; 68(3):e0106423. PubMed ID: 38349161
[TBL] [Abstract][Full Text] [Related]
19. Molecular dynamics simulations of human rhinovirus and an antiviral compound.
Speelman B; Brooks BR; Post CB
Biophys J; 2001 Jan; 80(1):121-9. PubMed ID: 11159387
[TBL] [Abstract][Full Text] [Related]
20. Structural studies on human rhinovirus 14 drug-resistant compensation mutants.
Hadfield AT; Oliveira MA; Kim KH; Minor I; Kremer MJ; Heinz BA; Shepard D; Pevear DC; Rueckert RR; Rossmann MG
J Mol Biol; 1995 Oct; 253(1):61-73. PubMed ID: 7473717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
